Dapagliflozin protects against MACE in acute MI patients undergoing PCI: Study

The study yielded the following findings:

· 130 patients had MACE (118 in the DAPA-free group and 12 in the DAPA group) during a median follow-up of 23 months.

· Kaplan–Meier survival analyses revealed that the cumulative incidence of MACE, heart failure, nonfatal MI, and URR was higher in the DAPA-free group.

· In addition, the multivariate Cox analysis showed that DAPA was significantly associated with the reduced risk of MACE (hazard ratio = 0.170).

· Considering each adverse event, the DAPA-free group was associated with heart failure, nonfatal MI, and URR in multivariate Cox regression analyses.

· Stratification analyses suggested that DAPA has a robust protective effect in patients with AMI of advanced age with concomitant diabetes or those not on angiotensin receptor enkephalinase inhibitors.

· The TyG index and AIP of the patients 12 months after DAPA administration at discharge were significantly lower than those during hospitalization.

"The findings showed that the administration of DAPA was linked to reduced MACE in AMI patients, specifically in those with hypertension and advanced age and those who did not receive ARNI," the researchers wrote. "Moreover, the study revealed that 12 months after discharge, DAPA administration remarkably decreased AIP and the TyG index."

Reference:

Zhu, Y., Zhang, Jl., Yan, Xj. et al. Effect of dapagliflozin on the prognosis of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Cardiovasc Diabetol 21, 186 (2022). https://doi.org/10.1186/s12933-022-01627-0